Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.54 |
| ▸ | MMP2 | P08253 | 6/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MMP15 | P51511 | 1/20 | 0.39 |
| ▸ | MMP16 | P51512 | 1/20 | 0.39 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6633344 | 0.78 | MMP9 (0.69) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL7355098 | 0.75 | MMP2 (0.70) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6629533 | 0.72 | MMP2 (0.41) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6628455 | 0.70 | MMP9 (1.00) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL5926084 | 0.67 | MMP2 (0.64) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6626999 | 0.66 | MMP2 (0.84) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6629399 | 0.65 | MMP2 (0.75) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL10691196 | 0.64 | ALOX5 (0.74) | ALOX5MAOB | |
| SCHEMBL6628975 | 0.64 | MMP2 (0.79) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6204405 | 0.63 | MMP2 (0.62) | ADAM17MMP2MMP9MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | claimed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | claimed |
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | ADAM17 3/4885MMP2 10/4885MMP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.